钠-葡萄糖协同转运蛋白2抑制剂、胰高血糖素样肽1激动剂与二肽基肽酶4抑制剂与2型糖尿病患者全因死亡率的关联:系统综述与网状Meta分析
该研究为网状Meta分析,纳入236项随机临床试验、共176310例2型糖尿病患者,随访至少12周,比较SGLT-2抑制剂、GLP-1激动剂和DPP-4抑制剂对死亡及心血管终点的影响。主要终点为全因死亡率。结果显示,与对照组相比,SGLT-2抑制剂(绝对风险差-1.0%;HR 0.80,95%CrI 0.71-0.89)和GLP-1激动剂(绝对风险差-0.6%;HR 0.88,95%CrI 0.81-0.94)与全因死亡率显著降低相关;DPP-4抑制剂与对照组相比无显著关联(绝对风险差0.1%;HR 1.02,95%CrI 0.94-1.11)。SGLT-2抑制剂和GLP-1激动剂的全因死亡率均低于DPP-4抑制剂。
要点
- 与对照组相比,SGLT-2抑制剂全因死亡率绝对风险差-1.0%(HR 0.80,95%CrI 0.71-0.89),GLP-1激动剂绝对风险差-0.6%(HR 0.88,95%CrI 0.81-0.94),均显著降低。
- 与DPP-4抑制剂相比,SGLT-2抑制剂全因死亡率绝对风险差-0.9%(HR 0.78,95%CrI 0.68-0.90),GLP-1激动剂绝对风险差-0.5%(HR 0.86,95%CrI 0.77-0.96)。
- DPP-4抑制剂与对照组相比全因死亡率无显著关联(绝对风险差0.1%;HR 1.02,95%CrI 0.94-1.11)。
- 与对照组相比,SGLT-2抑制剂心血管死亡率绝对风险差-0.8%(HR 0.79,95%CrI 0.69-0.91),GLP-1激动剂绝对风险差-0.5%(HR 0.85,95%CrI 0.77-0.94),均显著降低。
- GLP-1激动剂导致试验退出的不良事件风险高于SGLT-2抑制剂(绝对风险差5.8%;HR 1.80,95%CrI 1.44-2.25)和DPP-4抑制剂(绝对风险差3.1%;HR 1.93,95%CrI 1.59-2.35)。
适用人群与场景
- 纳入标准:随机临床试验入组的2型糖尿病患者,随访至少12周,比较SGLT-2抑制剂、GLP-1激动剂或DPP-4抑制剂与彼此、安慰剂或无治疗。
研究设计与关键结果
- 研究类型:贝叶斯分层网状Meta分析,纳入236项随机临床试验,共176310例2型糖尿病患者,检索MEDLINE、Embase、Cochrane Library Central Register of Controlled Trials及已发表Meta分析,检索时间自建库至2017年10月11日。
- 主要终点全因死亡率:与对照组相比,SGLT-2抑制剂绝对风险差-1.0%(HR 0.80,95%CrI 0.71-0.89),GLP-1激动剂绝对风险差-0.6%(HR 0.88,95%CrI 0.81-0.94),均显著降低;DPP-4抑制剂绝对风险差0.1%(HR 1.02,95%CrI 0.94-1.11),无显著关联。
- 全因死亡率头对头比较:SGLT-2抑制剂低于DPP-4抑制剂(绝对风险差-0.9%;HR 0.78,95%CrI 0.68-0.90),GLP-1激动剂低于DPP-4抑制剂(绝对风险差-0.5%;HR 0.86,95%CrI 0.77-0.96)。
- 心血管死亡率:与对照组相比,SGLT-2抑制剂绝对风险差-0.8%(HR 0.79,95%CrI 0.69-0.91),GLP-1激动剂绝对风险差-0.5%(HR 0.85,95%CrI 0.77-0.94),均显著降低。
- 心力衰竭事件:与对照组相比,SGLT-2抑制剂绝对风险差-1.1%(HR 0.62,95%CrI 0.54-0.72),显著降低。
- 心肌梗死:与对照组相比,SGLT-2抑制剂绝对风险差-0.6%(HR 0.86,95%CrI 0.77-0.97),显著降低。
- 安全性:GLP-1激动剂导致试验退出的不良事件风险高于SGLT-2抑制剂(绝对风险差5.8%;HR 1.80,95%CrI 1.44-2.25)和DPP-4抑制剂(绝对风险差3.1%;HR 1.93,95%CrI 1.59-2.35)。
证据类型、等级与局限
- 证据类型:系统综述与网状Meta分析(贝叶斯分层网状Meta分析),纳入236项随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:在此网状Meta分析中,使用SGLT-2抑制剂或GLP-1激动剂与低于DPP-4抑制剂或安慰剂或无治疗的死亡率相关;使用DPP-4抑制剂与低于安慰剂或无治疗的死亡率无关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The comparative clinical efficacy of sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors for treatment of type 2 diabetes is unknown.
OBJECTIVE: To compare the efficacies of SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors on mortality and cardiovascular end points using network meta-analysis.
DATA SOURCES: MEDLINE, Embase, Cochrane Library Central Register of Controlled Trials, and published meta-analyses from inception through October 11, 2017.
STUDY SELECTION: Randomized clinical trials enrolling participants with type 2 diabetes and a follow-up of at least 12 weeks were included, for which SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors were compared with either each other or placebo or no treatment.
DATA EXTRACTION AND SYNTHESIS: Data were screened by 1 investigator and extracted in duplicate by 2 investigators. A Bayesian hierarchical network meta-analysis was performed.
MAIN OUTCOMES AND MEASURES: The primary outcome: all-cause mortality; secondary outcomes: cardiovascular (CV) mortality, heart failure (HF) events, myocardial infarction (MI), unstable angina, and stroke; safety end points: adverse events and hypoglycemia.
RESULTS: This network meta-analysis of 236 trials randomizing 176 310 participants found SGLT-2 inhibitors (absolute risk difference [RD], -1.0%; hazard ratio [HR], 0.80 [95% credible interval {CrI}, 0.71 to 0.89]) and GLP-1 agonists (absolute RD, -0.6%; HR, 0.88 [95% CrI, 0.81 to 0.94]) were associated with significantly lower all-cause mortality than the control groups. SGLT-2 inhibitors (absolute RD, -0.9%; HR, 0.78 [95% CrI, 0.68 to 0.90]) and GLP-1 agonists (absolute RD, -0.5%; HR, 0.86 [95% CrI, 0.77 to 0.96]) were associated with lower mortality than were DPP-4 inhibitors. DPP-4 inhibitors were not significantly associated with lower all-cause mortality (absolute RD, 0.1%; HR, 1.02 [95% CrI, 0.94 to 1.11]) than were the control groups. SGLT-2 inhibitors (absolute RD, -0.8%; HR, 0.79 [95% CrI, 0.69 to 0.91]) and GLP-1 agonists (absolute RD, -0.5%; HR, 0.85 [95% CrI, 0.77 to 0.94]) were significantly associated with lower CV mortality than were the control groups. SGLT-2 inhibitors were significantly associated with lower rates of HF events (absolute RD, -1.1%; HR, 0.62 [95% CrI, 0.54 to 0.72]) and MI (absolute RD, -0.6%; HR, 0.86 [95% CrI, 0.77 to 0.97]) than were the control groups. GLP-1 agonists were associated with a higher risk of adverse events leading to trial withdrawal than were SGLT-2 inhibitors (absolute RD, 5.8%; HR, 1.80 [95% CrI, 1.44 to 2.25]) and DPP-4 inhibitors (absolute RD, 3.1%; HR, 1.93 [95% CrI, 1.59 to 2.35]).
CONCLUSIONS AND RELEVANCE: In this network meta-analysis, the use of SGLT-2 inhibitors or GLP-1 agonists was associated with lower mortality than DPP-4 inhibitors or placebo or no treatment. Use of DPP-4 inhibitors was not associated with lower mortality than placebo or no treatment.
参考来源
- Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA. 2018. PMID: 29677303. doi:10.1001/jama.2018.3024
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。